Приобретенные кожно-легочные синдромы

Поражения кожи и ее придатков на фоне заболеваний органов дыхания являются достаточно частым явлением, наблюдаемым в рутинной клинической практике. Патологические изменения кожи и ее придатков могут манифестировать в качестве проявления мультисистемного генетического заболевания как проявление хронических заболеваний легких или в качестве приобретенных синдромов с сочетанным поражением кожи, ее придатков и органов дыхания. Патологические изменения кожи и ее придатков на фоне поражения органов дыхания могут быть обусловлены наличием тяжелой системной патологии (синдром Базекса, гранулематоз с полиангиитом, синдром Лефгрена), но в то же время могут быть единственным клиническим признаком заболевания (синдром желтых ногтей). Целью работы является описание клинической картины приобретенных кожно-легочных синдромов (ПКЛС), включая синдром Базекса, гранулематоз с полиангиитом, синдром Лефгрена и синдром желтых ногтей, эозинофильный гранулематоз с полиангиитом и синдром Шегрена, с акцентом на известные клинические проявления со стороны кожи, ее придатков и органов дыхания. Заключение. Выявление отдельных симптомов и синдромального компонента конкретного заболевания является очень сложной задачей, при решении которой требуются глубокие академические и клинические знания со стороны врача. Разнообразие клинических поражений кожи, ее придатков и органов дыхания в рамках ПКЛС может представлять трудности в рамках рутинного приема. В рамках данной статьи предпринята попытка описать основные приобретенные ПКЛС, встречающиеся в рутинной практике как пульмонолога, так и дерматолога, с акцентом на клинические проявления данных синдромов со стороны кожи, ее придатков и органов дыхания.

1. Saad Abdalrazik F., Bedair N.I., Yassen N.N. Skin aging in patients with chronic obstructive pulmonary disease of different ages. Egypt. J. Chest Dis. Tuberc. 2021; 70 (3): 325–330. DOI: 10.4103/ejcdt.ejcdt_215_19.

2. Melzer T., Graf V., Kronseder A. et al. Skin markers of premature ageing in patients with COPD: results form COSYCONET. J. Clin. Med. 2024; 13 (22): 6972. DOI: 10.3390/jcm13226972.

3. Motswaledi M.H., Mayayise M.C. Nail changes in systemic diseases. S. Afr. Fam. Pract. 2010; 52 (5): 409–413. DOI: 10.1080/20786204.2010.10874016.

4. Federación Española de Enfermedades Raras. Available at: https://www.enfermedades-raras.org/enfermedades-raras [Accessed: January 6, 2022].

5. Birt A.R., Hogg G.R., Dubé W.J. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch. Dermatol. 1977; 113 (12): 1674–1677. Available at: https://jamanetwork.com/journals/jamadermatology/article-abstract/538004

6. Cortini F., Villa C. Ehlers-Danlos syndromes and epilepsy: an updated review. Seizure. 2018; 57: 1–4. DOI: 10.1016/j.seizure.2018.02.013.

7. Solares I., Vinal D., Morales-Conejo M. Diagnostic and follow-up protocol for adult patients with neurofibromatosis type 1 in a Spanish reference unit. Rev. Clin. Esp. (Barc.). 2022; 222 (8): 486–495. DOI: 10.1016/j.rceng.2022.02.007.

8. Hyman M.H., Whittemore V.H. National Institutes of health consensus conference: tuberous sclerosis complex. Arch. Neurol. 2000; 57 (5): 662–665. DOI: 10.1001/archneur.57.5.662.

9. Naganathan S., Tadi P. Klippel–Trenaunay–Weber Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025: NBK558989. Available at: https://www.ncbi.nlm.nih.gov/books/NBK558989/

10. Berk D.R., Bentley D.D., Bayliss S.J. et al. Cutis laxa: a review. J. Am. Acad. Dermatol. 2012; 66 (5): 842.e1–17. DOI: 10.1016/j.jaad.2011.01.004.

11. Hermansky F., Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood. 1959; 14 (2): 162–169. Blood. 2016; 127 (14):1731. DOI: 10.1182/blood-2016-01-696435.

12. Dokal I. Dyskeratosis congenita in all its forms. Br. J. Haematol. 2000; 110 (4): 768–779. DOI: 10.1046/j.1365-2141.2000.02109.x.

13. Bazex A., Salvador R., Dupre A., Christol B. Syndrome paraneoplasieque a type d’hyperkeratose des extremites. Guerison apres le traitement de l’epithelioma larynge. Bull. Soc. Fr. Dermatol. Syphiligr. 1965; 72: 182.

14. Amano M., Hanafusa T., Chikazawa S. et al. Bazex syndrome in lung squamous cell carcinoma: high expression of epidermal growth factor receptor in lesional keratinocytes with Th2 immune shift. Case Rep. Dermatol. 2016; 8 (3): 358–362. DOI: 10.1159/000452827.

15. Bolognia J.L., Brewer Y.P., Cooper D.L. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. Medicine (Baltimore). 1991; 70 (4): 269–280. DOI: 10.1097/00005792-199107000-00004.

16. Eckstein J., Healy E., Jain A. et al. A series of typical and atypical cases of Bazex syndrome: Identifying the red herring to avoid delaying cancer treatment. Clin. Case Rep. 2020; 8 (11): 2259–2264. DOI: 10.1002/ccr3.3133.

17. Stone S.P., Buescher L.S. Life-threatening paraneoplastic cutaneous syndromes. Clin. Dermatol. 2005; 23 (3): 301–306. DOI: 10.1016/j.clindermatol.2004.06.011.

18. Bazex A., Griffiths A. Acrokeratosis paraneoplastica – a new cutaneous marker of malignancy. Br. J. Dermatol. 1980; 103 (3): 301–306. DOI: 10.1111/j.1365-2133.1980.tb07248.x.

19. Sharma V., Sharma N.L., Ranjan N. et al. Acrokeratosis paraneoplastica (Bazex syndrome): case report and review of literature. Dermatol. Online J. 2006; 12 (1): 11. DOI: 10.5070/D34fz6f008.

20. Zarzour J.G., Singh S., Andea A., Cafardi J.A. Acrokeratosis paraneoplastica (Bazex syndrome): report of a case associated with small cell lung carcinoma and review of the literature. J. Radiol. Case Rep. 2011; 5 (7): 1–6. DOI: 10.3941/jrcr.v5i7.663.

21. Hsu Y.S., Lien G.S., Lai H.H. et al. Acrokeratosis paraneoplastica (Bazex syndrome) with adenocarcinoma of the colon: report of a case and review of the literature. J. Gastroenterol. 2000; 35 (6): 460–464. DOI: 10.1007/s005350070092.

22. Hempen A., Samartzis E.P., Kamarachev J. et al. Acrokeratosis paraneoplastica in serous ovarian carcinoma: case report. BMC Cancer. 2015; 15: 507. DOI: 10.1186/s12885-015-1527-z.

23. Mititelu R., Powell M. A case report of resolution of acrokeratosis paraneoplastica (Bazex syndrome) post resection of non-small-cell lung carcinoma. SAGE Open Med. Case Rep. 2019; 7: 2050313X19881595. DOI: 10.1177/2050313X19881595.

24. Pecora A.L., Landsman L., Imgrund S.P., Lambert W.C. Acrokeratosis paraneoplastica (Bazex' syndrome). Report of a case and review of the literature. Arch. Dermatol. 1983; 119 (10): 820-826. DOI: 10.1001/archderm.119.10.820.

25. Ikeda K., Kanno K., Otani Y., Ito M. A case of Bazex syndrome. Intern Med. 2022; 61 (3): 443–444. DOI: 10.2169/internalmedicine.7568-21.

26. Aoshima Y., Karayama M., Sagisaka S. et al. Synchronous occurrence of Bazex syndrome and remitting seronegative symmetrical synovitis with pitting edema syndrome in a patient with lung cancer. Intern Med. 2019, 58 (22): 3267–3271. DOI: 10.2169/internalmedicine.3032-19.

27. Zhao J., Zhang X., Chen Z., Wu J.H. Case report: Bazex syndrome associated with pulmonary adenocarcinoma. Medicine (Baltimore). 2016; 95 (2): e2415. DOI: 10.1097/MD.0000000000002415.

28. George C., Diaz-Cano S., Creamer D. An unusual cause for a psoriasiform dermatosis. Clin. Exp. Dermatol. 2017; 42 (1): 115–117. DOI: 10.1111/ced.12992.

29. Fleming J.D., Stefanato C.M., Attard N.R. Bazex syndrome (acrokeratosis paraneoplastica). Clin. Exp. Dermatol. 2014; 39 (8): 955–956. DOI: 10.1111/ced.12353.

30. Humphrey S.R., Hussain A.S., Chandran R. et al. Acute onset of acrokeratosis paraneoplastica (Bazex syndrome). JAMA Dermatol. 2015; 151 (6): 677–678. DOI: 10.1001/jamadermatol.2014.5622.

31. Dabas G., De D., Handa S. et al. Acrokeratosis paraneoplastica (Bazex syndrome). QJM. 2018; 111 (1): 63–64. DOI: 10.1093/qjmed/hcx187.

32. Peixoto L., Aguiar P., Veloso Gomes F. et al. Nogueira Wegener’s granulomatosis. In: Amezcua-Guerra L.M., ed. Advances in the etiology, pathogenesis and pathology of vasculitis. IntechOpen; 2011; Ch. 11: 225–234. DOI: 10.5772/20014.

33. Klinger H. Grenzformen der pericarditis nodosa. Frankfurt Zeitschr Pathol. 1931; 42: 455–480.

34. Fauci A.S., Wolff S.M. Wegener´s granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore). 1973; 52 (6): 535–561. DOI: 10.1097/00005792-197311000-00002.

35. Kallenberg C.G. Pathogenesis of ANCA-associated vasculitides. Ann. Rheum. Dis. 2011; 70 (Suppl. 1): i59–63. DOI: 10.1136/ard.2010.138024.

36. Jayne D. The diagnosis of vasculitis. Best Pract. Res. Clin. Rheumatol. 2009; 23 (3): 445–453. DOI: 10.1016/j.berh.2009.03.001.

37. Manganelli P., Fietta P., Carotti M. et al. Respiratory system involvement in systemic vasculitides. Clin. Exp. Rheumatol. 2006; 24 (2, Suppl. 41): S48–59. Available at: https://www.clinexprheumatol.org/abstract.asp?a=2846

38. Merkel P.A., Lo G.H., Holbrook J.T. et al. Wegener's granulomatosis etanercept trial research group. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's clinical occurrence of thrombosis (WeCLOT) study. Ann. Intern Med. 2005; 142 (8): 620–626. DOI: 10.7326/0003-4819-142-8-200505030-00011.

39. Harper S.L., Letko E., Samson C.M. et al. Wegener's granulomatosis: the relationship between ocular and systemic disease. J. Rheumatol. 2001; 28 (5): 1025–1032. Available at: https://www.jrheum.org/content/28/5/1025

40. Shafiei K., Luther E., Archie M. et al. Wegener granulomatosis: case report and brief literature review. J. Am. Board Fam. Pract. 2003; 16 (6): 555–559. DOI: 10.3122/jabfm.16.6.555.

41. Ungprasert P., Crowson C.S., Matteson E.L. Clinical characteristics of sarcoid arthropathy: a population-based study. Arthritis Care Res. (Hoboken). 2016; 68 (5): 695–699. DOI: 10.1002/acr.22737.

42. Visser H., Vos K., Zanelli E. et al. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann. Rheum. Dis. 2002; 61 (6): 499–504. DOI: 10.1136/ard.61.6.499.

43. Llanos O., Hamzeh N. Sarcoidosis. Med. Clin. North Am. 2019; 103 (3): 527–534. DOI: 10.1016/j.mcna.2018.12.011.

44. Lofgren S. Primary pulmonary sarcoidosis. I. Early signs and symptoms. Acta Med. Scand. 1953; 145 (6): 424–431. DOI: 10.1111/j.0954-6820.1953.tb07039.x.

45. Flores R., Caridade S. Löfgren syndrome: clinical presentation, clinical course, and literature review. Cureus. 2023; 15 (1): e33651. DOI: 10.7759/cureus.33651.

46. Debashis M., Amrita P., Pratima S., Prasanta P. Lofgren syndrome: not an uncommon entity. J. Int. Med. Res. 2023; 1 (1): 25–28. DOI: 10.4103/jimr.jimr_5_22.

47. Wanat K.A., Rosenbach M. Cutaneous sarcoidosis. Clin. Chest Med. 2015; 36 (4): 685–702. DOI: 10.1016/j.ccm.2015.08.010.

48. Arthritis in sarcoidosis group (ASG); Agarwal V., Agrawal V., Aggarwal A. et al. Arthritis in sarcoidosis: a multicentric study from India. Int. J. Rheum. Dis. 2018; 21 (9): 1728–1733. DOI: 10.1111/1756-185X.13349.

49. Rochepeau C., Jamilloux Y., Kerever S. et al. Long-term visual and systemic prognoses of 83 cases of biopsy-proven sarcoid uveitis. Br. J. Ophthalmol. 2017; 101 (7): 856–861. DOI: 10.1136/bjophthalmol-2016-309767.

50. Hiller E., Rosenow E.C. 3rd, Olsen A.M. Pulmonary manifestations of the yellow nail syndrome. Chest. 1972; 61 (5): 452–458. DOI: 10.1378/chest.61.5.452.

51. Heller J. Die krankheiten der nägel. Berlin: Springer. 1927; 13 (Pt 2). DOI: 10.1007/978-3-642-91683-0.

52. Samman P.D., White W.F. The “Yellow nail” syndrome. Br. J. Dermatol. 1964; 76: 153–157. DOI: 10.1111/j.1365-2133.1964.tb14499.

53. Maldonado F., Ryu J.H. Yellow nail syndrome. Curr. Opin. Pulm. Med. 2009; 15 (4): 371–375. DOI: 10.1097/MCP.0b013e32832ad45a.

54. Decker A., Daly D., Scher R.K. Role of titanium in the development of yellow nail syndrome. Skin. Appendage Disord. 2015; 1 (1): 28–30. DOI: 10.1159/000375171.

55. Piraccini B.M., Urciuoli B., Starace M. et al. Yellow nail syndrome: clinical experience in a series of 21 patients. J. Dtsch. Dermatol. Ges. 2014; 12 (2): 131–137. DOI: 10.1111/ddg.12216.

56. Nordkild P., Kromann-Andersen H., Struve-Christensen E. Yellow nail syndrome – the triad of yellow nails, lymphedema and pleural effusions. A review of the literature and a case report. Acta Med. Scand. 1986; 219 (2): 221–227. DOI: 10.1111/j.0954-6820.1986.tb03302.x.

57. Varney V.A., Cumberworth V., Sudderick R. et al. Rhinitis, sinusitis and the yellow nail syndrome: a review of symptoms and response to treatment in 17 patients. Clin. Otolaryngol. Allied. Sci. 1994; 19 (3): 237–240. DOI: 10.1111/j.1365-2273.1994.tb01222.x.

58. Pavlidakey G.P., Hashimoto K., Blum D. Yellow nail syndrome. J. Am. Acad. Dermatol. 1984; 11 (3): 509–512. DOI: 10.1016/s0190-9622(84)70201-5.

59. Maisels D.O., Korachi A.O. Lymphoedema of the eyelids in the yellow nail syndrome. Br. J. Plast Surg. 1985; 38 (1): 93–96. DOI: 10.1016/0007-1226(85)90093-1.

60. Bourcier T., Baudrimont M., Borderie V. et al. Conjunctival changes associated with yellow nail syndrome. Br. J. Ophthalmol. 2002; 86 (8): 930. DOI: 10.1136/bjo.86.8.930.

61. Гостева Т.А., Клеузович В.М., Саранюк Р.В. Синдром желтых ногтей: серия из двух клинических случаев и обзор литературы. Вестник дерматологии и венерологии. 2024; 100 (5): 89–96. DOI: 10.25208/vdv16771.

62. Stosiek N., Peters K.P., Hiller D. et al. Yellow nail syndrome in a patient with mycosis fungoides. J. Am. Acad. Dermatol. 1993; 28 (5, Pt 1): 792–794. DOI: 10.1016/s0190-9622(09)80277-6.

63. Churg J., Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am. J. Pathol. 1951; 27 (2): 277–301. Available at: https://scispace.com/papers/allergic-granulomatosis-allergic-angiitis-and-periarteritis-4mmqsaji3q

64. Jennette J.C., Falk R.J., Andrassy K. et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994; 37 (2): 187–192. DOI: 10.1002/art.1780370206.

65. Chakraborty R.K., Aeddula N.R. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK537099/

66. Knockaert D.C. Cardiac involvement in systemic inflammatory diseases. Eur. Heart J. 2007; 28 (15): 1797–1804. DOI: 10.1093/eurheartj/ehm193.

67. Boggi U., Mosca M., Giulianotti P.C. et al. Surviving catastrophic gastrointestinal involvement due to Churg–Strauss syndrome: report of a case. Hepatogastroenterology. 1997; 44 (16): 1169–1171.

68. Pagnoux C., Guillevin L. Churg–Strauss syndrome: evidence for disease subtypes? Curr. Opin. Rheumatol. 2010; 22 (1): 21–28. DOI: 10.1097/BOR.0b013e328333390b.

69. Ewert B.H., Jennette J.C., Falk R.J. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int. 1992; 41 (2): 375–383. DOI: 10.1038/ki.1992.52.

70. Oiwa H., Mokuda S., Matsubara T. et al. Neurological complications in eosinophilic granulomatosis with polyangiitis (EGPA): the roles of history and physical examinations in the diagnosis of EGPA. Intern. Med. 2017; 56 (22): 3003–3008. DOI: 10.2169/internalmedicine.8457-16.

71. Mavragani C.P., Moutsopoulos H.M. The geoepidemiology of Sjögren's syndrome. Autoimmun. Rev. 2010; 9 (5): A305–A310. DOI: 10.1016/j.autrev.2009.11.004.

72. Skopouli F.N., Dafni U., Ioannidis J.P., Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin. Arthritis Rheum. 2000; 29 (5): 296–304. DOI: 10.1016/s0049-0172(00)80016-5.

73. Papiris S.A., Maniati M., Constantopoulos S.H. et al. Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann. Rheum. Dis. 1999; 58 (1): 61–64. DOI: 10.1136/ard.58.1.61.

74. Papiris S.A., Tsonis I.A., Moutsopoulos H.M. Sjogren's syndrome. Semin. Respir. Crit. Care Med. 2007; 28: 459–471. DOI: 10.1055/s-2007-985667.

75. Mavragani C.P., Moutsopoulos H.M. Sjögren syndrome. CMAJ. 2014; 186 (15): E579–586. DOI: 10.1503/cmaj.122037.

76. Tsokos M., Lazarou S.A., Moutsopoulos H.M. Vasculitis in primary Sjögren's syndrome. Histologic classification and clinical presentation. Am. J. Clin. Pathol. 1987; 88 (1): 26–31. DOI: 10.1093/ajcp/88.1.26.

77. Ramos-Casals M., Anaya J.M., García-Carrasco M. et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004; 83 (2): 96–106. DOI: 10.1097/01.md.0000119465.24818.98.

78. Skopouli F.N., Talal A., Galanopoulou V. et al. Raynaud's phenomenon in primary Sjögren's syndrome. J. Rheumatol. 1990; 17 (5): 618–620.

79. Tsampoulas C.G., Skopouli F.N., Sartoris D.J. et al. Hand radiographic changes in patients with primary and secondary Sjögren's syndrome. Scand. J. Rheumatol. 1986; 15 (3): 333–339. DOI: 10.3109/03009748609092600.

80. Kassan S.S., Moutsopoulos H.M. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch. Intern. Med. 2004; 164 (12): 1275–1284. DOI: 10.1001/archinte.164.12.1275.

81. Skopouli F.N., Barbatis C., Moutsopoulos H.M. Liver involvement in primary Sjögren's syndrome. Br. J. Rheumatol. 1994; 33 (8): 745–748. DOI: 10.1093/rheumatology/33.8.745.

82. Goules A., Masouridi S., Tzioufas A.G. et al. Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore). 2000; 79 (4): 241–249. DOI: 10.1097/00005792-200007000-00005.

83. Mavragani C.P., Fragoulis G.E., Moutsopoulos H.M. Endocrine alterations in primary Sjogren's syndrome: an overview. J. Autoimmun. 2012; 39 (4): 354–358. DOI: 10.1016/j.jaut.2012.05.011.

84. Brito-Zerón P., Akasbi M., Bosch X. et al. Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren's syndrome. Clin. Exp. Rheumatol. 2013; 31 (1): 103–110. Available at: https://www.clinexprheumatol.org/abstract.asp?a=5938

85. Pavlakis P.P., Alexopoulos H., Kosmidis M.L. et al. Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J. Neurol. Neurosurg Psychiatry. 2011; 82 (7): 798–802. DOI: 10.1136/jnnp.2010.222109.

86. Voulgarelis M., Ziakas P.D., Papageorgiou A. et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore). 2012; 91 (1): 1–9. DOI: 10.1097/MD.0b013e31824125e4